drugset / Trial / NCT02392910
Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.
RandomizedParallel-groupDouble-blindTreatment
Summary
Iron deficiency, independent of anemia, appears to increase morbidity and mortality as well as impairing health-related quality of life in chronic heart failure (CHF), and these effects are compounded when patients also experience chronic kidney disease (CKD). This study was designed to determine the effects of intravenous iron treatment on morbidity and mortality following an initial 6-month period and a longer period of up to 5 years.
Timeline
- Start
- 2006-03
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iron sucrose | Unknown | 200 mg | Intravenous |